{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:53:31Z","timestamp":1767988411033,"version":"3.49.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We assessed the teratogenicity of tenofovir, a human immunodeficiency virus (HIV) drug similar to remdesivir that is currently being evaluated for the treatment of coronavirus disease 2019 (COVID-19). Using US Medicaid Analytic eXtract (MAX) claims data (2000\u20132014), we identified a population-based pregnancy cohort of women with HIV who filled at least 1 prescription for antiretroviral therapies (ART) during the first trimester. Women on tenofovir disoproxil fumarate (TDF) were compared with women receiving ART without TDF. Major malformations were identified by International Classification of Diseases, Ninth Revision, codes using validated algorithms. Relative risks and 95% confidence intervals were estimated using propensity score stratification to control for potential confounders. We incorporated the results into prior knowledge by conducting a systematic literature review and a meta-analysis. Major congenital malformations were diagnosed in 37 out of 866 (4.27%) infants exposed to TDF and 38 out of 1,020 (3.73%) infants exposed to ART other than TDF; the adjusted relative risk was 1.21 (95% confidence interval: 0.77, 1.90). Estimates for specific malformations were imprecise. The pooled relative risk from the meta-analysis with 6 prior studies was 0.88 (95% confidence interval: 0.75, 1.03). Based on evidence accumulated in patients with HIV, first-trimester TDF use does not increase the risk of major congenital malformations overall in the newborn compared with other ART.<\/jats:p>","DOI":"10.1093\/aje\/kwab109","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T03:28:38Z","timestamp":1618025318000},"page":"2339-2349","source":"Crossref","is-referenced-by-count":12,"title":["Safety of Tenofovir Disoproxil Fumarate for Pregnant Women Facing the Coronavirus Disease 2019 Pandemic"],"prefix":"10.1093","volume":"190","author":[{"given":"Sonia","family":"Hern\u00e1ndez-D\u00edaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreen","family":"Straub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Mogun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista F","family":"Huybrechts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"issue":"8","key":"2021110206563783200_ref1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"10226","key":"2021110206563783200_ref2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(20)30360-3","article-title":"Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2021110206563783200_ref3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajogmf.2020.100118","article-title":"Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals","volume":"2","author":"Breslin","year":"2020","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"25","key":"2021110206563783200_ref4","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1056\/NEJMc2009226","article-title":"Clinical characteristics of pregnant women with Covid-19 in Wuhan, China","volume":"382","author":"Chen","year":"2020","journal-title":"N Engl J Med"},{"issue":"44","key":"2021110206563783200_ref5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.15585\/mmwr.mm6944e3","article-title":"Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status\u2014United States, January 22\u2013October 3, 2020","volume":"69","author":"Zambrano","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"25","key":"2021110206563783200_ref6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.15585\/mmwr.mm6925a1","article-title":"Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status\u2014United States, January 22\u2013June 7, 2020","volume":"69","author":"Ellington","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10226","key":"2021110206563783200_ref7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(20)30365-2","article-title":"What are the risks of COVID-19 infection in pregnant women?","volume":"395","author":"Qiao","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2021110206563783200_ref8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.21037\/tp.2020.02.06","article-title":"Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia","volume":"9","author":"Zhu","year":"2020","journal-title":"Transl Pediatr"},{"issue":"5","key":"2021110206563783200_ref9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/cid\/ciaa226","article-title":"Perinatal transmission of 2019 coronavirus disease-associated severe acute respiratory syndrome coronavirus 2: should we worry?","volume":"72","author":"Fan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"18","key":"2021110206563783200_ref10","first-page":"1846","article-title":"Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn","volume":"323","author":"Dong","year":"2020","journal-title":"JAMA"},{"issue":"18","key":"2021110206563783200_ref11","first-page":"1848","article-title":"Antibodies in infants born to mothers with COVID-19 pneumonia","volume":"323","author":"Zeng","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"2021110206563783200_ref12","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J Proteome Res"},{"key":"2021110206563783200_ref13","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"2021110206563783200_ref14","author":"Salazar","year":"2020","journal-title":"Digital CSIC"},{"issue":"3","key":"2021110206563783200_ref15","doi-asserted-by":"crossref","first-page":"e01114","DOI":"10.1128\/mBio.01114-20","article-title":"Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets","volume":"11","author":"Park","year":"2020","journal-title":"MBio"},{"issue":"7","key":"2021110206563783200_ref16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7326\/M20-3689","article-title":"Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study","volume":"173","author":"Del Amo","year":"2020","journal-title":"Ann Intern Med"},{"issue":"6","key":"2021110206563783200_ref17","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/EDE.0000000000001235","article-title":"Antiretrovirals and risk of COVID-19 diagnosis and hospitalization in HIV-positive persons","volume":"31","author":"Del Amo","year":"2020","journal-title":"Epidemiology"},{"key":"2021110206563783200_ref18","author":"Davies"},{"key":"2021110206563783200_ref19","author":"ClinicalTrial.gov Record"},{"issue":"19","key":"2021110206563783200_ref20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"2021110206563783200_ref21","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"2021110206563783200_ref22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067405","article-title":"Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations","volume":"8","author":"Palmsten","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"2021110206563783200_ref23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/QAD.0000000000001549","article-title":"Zidovudine use in pregnancy and congenital malformations","volume":"31","author":"Rough","year":"2017","journal-title":"AIDS"},{"issue":"8","key":"2021110206563783200_ref24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/INF.0b013e3181e74a2f","article-title":"Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C","volume":"29","author":"Brogly","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021110206563783200_ref25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/INF.0b013e318235c7aa","article-title":"Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals","volume":"31","author":"Knapp","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2021110206563783200_ref26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamapediatrics.2014.1889","article-title":"Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants","volume":"169","author":"Williams","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"4","key":"2021110206563783200_ref27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001635","article-title":"Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1\/CO11)","volume":"11","author":"Sibiude","year":"2014","journal-title":"PLoS Med"},{"issue":"5","key":"2021110206563783200_ref28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00042560-200204150-00009","article-title":"Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission","volume":"29","author":"Cooper","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"18","key":"2021110206563783200_ref29","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","article-title":"Benefits and risks of antiretroviral therapy for perinatal HIV prevention","volume":"375","author":"Fowler","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2021110206563783200_ref30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/apc.2013.0165","article-title":"Trends in antiretroviral drug use during pregnancy among HIV-infected women on Medicaid: 2000\u20132007","volume":"28","author":"Phiri","year":"2014","journal-title":"AIDS Patient Care STDS"},{"issue":"17","key":"2021110206563783200_ref31","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJMoa1701666","article-title":"Birth outcomes for pregnant women with HIV using tenofovir-emtricitabine","volume":"378","author":"Rough","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2021110206563783200_ref32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/pds.1534","article-title":"Positive predictive value of computerized records for major congenital malformations","volume":"17","author":"Cooper","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"2021110206563783200_ref33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/pds.3627","article-title":"Validity of maternal and infant outcomes within nationwide Medicaid data","volume":"23","author":"Palmsten","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"2021110206563783200_ref34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pds.4967","article-title":"Validation of algorithms to identify adverse perinatal outcomes in the Medicaid Analytic Extract database","volume":"29","author":"He","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"7","key":"2021110206563783200_ref35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/INF.0000000000000251","article-title":"First trimester exposure to antiretroviral therapy and risk of birth defects","volume":"33","author":"Phiri","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2021110206563783200_ref36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"Propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"key":"2021110206563783200_ref37","author":"Antiretroviral Pregnancy Registry Steering Committee","year":"2019"},{"issue":"12","key":"2021110206563783200_ref38","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/1471-0528.12285","article-title":"Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001--2011","volume":"120","author":"Floridia","year":"2013","journal-title":"BJOG"},{"issue":"1","key":"2021110206563783200_ref39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis","volume":"63","author":"Brown","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"2021110206563783200_ref40","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/cid\/civ437","article-title":"Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy","volume":"61","author":"Siberry","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2021110206563783200_ref41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/cid\/ciy982","article-title":"Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus","volume":"69","author":"Salvadori","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021110206563783200_ref42","author":"World Health Organization","year":"2016"},{"key":"2021110206563783200_ref43","author":"Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission","year":"2016"},{"issue":"6","key":"2021110206563783200_ref44","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/ppe.12650","article-title":"Quantification of selection bias in studies of risk factors for birth defects among livebirths","volume":"34","author":"Heinke","year":"2020","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"13","key":"2021110206563783200_ref45","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/1471-0528.13297","article-title":"The Obstetric Comorbidity Index predicts severe maternal morbidity","volume":"122","author":"Bateman","year":"2015","journal-title":"BJOG"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwab109\/40346325\/kwab109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/190\/11\/2339\/41025330\/kwab109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/190\/11\/2339\/41025330\/kwab109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T06:58:36Z","timestamp":1635836316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/190\/11\/2339\/6224946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,4,13]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwab109","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,4,13]]}}}